As at Nov 18, the clinic has an issued and paid-up share capital of $100,000 comprising 100,000 ordinary shares.
According to the group, the acquisition represents “a good opportunity for the group to build shareholder value and strengthen its financial position”.
On a pro forma basis, had the acquisition been completed on Jan 1, 2023, the group’s losses for the FY2023 would have stood at $8.5 million instead of a loss of $8.4 million. Loss per share would have stood at 1.24 cents, instead of a loss per share of 1.31 cents.
Shares in Meta Health closed flat at 7 cents on Nov 18.
See also: Q&M issues letter of demand to Aoxin Q&M’s group CEO
Scroll to continue
